John Libbey Eurotext

European Journal of Dermatology


Diffuse hair loss following anti-programmed cell death-1 antibody treatment: a case report with immunohistochemical analysis Volume 29, numéro 3, May-June 2019


  • Figure 1
1 Department of Dermatology,
2 Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Japan, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Programmed cell death 1 (PD-1) is an immune checkpoint receptor that mediates the suppression of activated T lymphocytes [1]. Anti-PD-1 antibodies, including nivolumab, facilitate T-lymphocyte activities by preventing PD ligand 1 (PD-L1) from binding to PD-1 [1]. Previous reports have described that anti-PD-1 antibodies can induce various types of immune-related adverse events (irAEs) [1, 2]. Dermatological irAEs include hair loss [1], and diffuse hair loss significantly affects patients’ quality [...]